Prostate cancer drugs: Will Medicare fix the drug payment system?

Why This Topic Matters

Prostate cancer drug reimbursement can significantly affect practice finances, and payment method changes may alter how these therapies are billed and paid. The article also helps coding and billing staff understand the HCPCS landscape for major prostate cancer injectable drugs discussed in the context of Medicare policy.

Article Sections

1. Medicare drug payment reform and reimbursement context

   Overview of Medicare’s proposed payment approaches for Part B drugs and the broader reimbursement environment affecting urology practices. Discusses the policy context and potential impact on provider payments.

2. Coverage and least costly alternative considerations

   General discussion of carrier coverage practices that may affect billing for these therapies. Addresses the role of local policies and the broader compliance and coding implications for drug selection.

3. LH/RH agonists for prostate cancer and their HCPCS codes

   Lists the injectable prostate cancer drug products discussed in the article and presents their HCPCS coding references. Includes the article’s billing-focused coding summary for these therapies.